Citizens says Ocular Therapeutix (OCUL) shares are down 25% as the market weighs how Axpaxli could fit into clinical practice when the Eylea control performed “valiantly” in the SOL-1 data Phase 3 study. The firm believes the market is losing “the forest through the trees.” There “should be no debate that Axpaxli is closer to approval today than on Friday,” the analyst tells investors in a research note. Citizens the stock selloff as an attractive entry point and reiterates an Outperform rating on Ocular Therapeutix with a $34 price target The stock in afternoon trading is down 22% to $6.95.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Midday Fly By: Warner Bros. reopens Paramount talks
- Ocular Therapeutix: SOL-1 Data Validate Axpaxli and Overdone Sell-Off Supports Buy Rating
- Jefferies stays constructive on Ocular Therapeutix despite SOL-1 selloff
- Ocular Therapeutix announces SOL-1 Phase 3 of Axpaxli met primary endpoint
- Regulatory Turbulence Threatens Ocular Therapeutix: FDA Disruptions and Global Delays Raise Approval and Funding Risks